espiratory Failure Complicated with Cardiac Dysfunction
Conditions
Interventions
VV-ECMO + IABP group vs. VV-ECMO group:None
Sponsors
Dongguan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients meeting all of the following criteria were included in this study: 1) Age = 18 years; 2. Initiation of VV-ECMO due to respiratory failure; 3. Evidence of cardiac dysfunction during VV-ECMO, defined as meeting any of the following conditions during VV-ECMO support: (1) Right ventricular dysfunction: manifested as tricuspid annular plane systolic excursion (TAPSE) < 17 mm, right ventricular dilation, or moderate to severe tricuspid regurgitation; (2) Left ventricular systolic dysfunction: left ventricular ejection fraction (LVEF) < 45%; (3) Persistent circulatory failure after correction of severe hypoxemia and acidosis, manifested as: 1) Persistent requirement for moderate to high doses of vasoactive or inotropic agents; 2) Elevated central venous pressure, impaired lactate clearance, or other abnormalities in indicators of systemic hypoperfusion.
Exclusion criteria
Exclusion criteria: 1. Initial extracorporeal circulation method is veno-arterial (VA-ECMO) or veno-arterial-venous (V-A-V) ECMO; 2. Intra-aortic balloon pump (IABP) implanted prior to initiation of VV-ECMO; 3. Cardiac arrest with receipt of extracorporeal cardiopulmonary resuscitation (ECPR); 4. ECMO support duration <24 hours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day ventilator-free days; | — |
Secondary
| Measure | Time frame |
|---|---|
| 14-day cumulative exposure dose of vasopressors; | — |
Countries
China
Contacts
Public ContactShen Lihan
Dongguan People's Hospital
Outcome results
None listed